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Abstract Extended adjuvant endocrine therapy (10 vs.
5 years) trials have demonstrated improved outcomes in
early-stage estrogen receptor (ER)-positive breast cancer;
however, the absolute benefit is modest, and toxicity and
tolerability challenges remain. Predictive and prognostic
information from genomic analysis may help inform this
clinical decision. The purpose of this study was to assess
the impact of the Breast Cancer Index (BCI) on physician
recommendations for extended endocrine therapy and on
patient anxiety and decision conflict. Patients with stage I–
III, ER-positive breast cancer who completed at least
3.5 years of adjuvant endocrine therapy were offered par-
ticipation. Genomic classification with BCI was performed
on archived tumor tissues and the results were reported to
the treating physician who discussed results with the
patient. Patients and physicians completed pre- and post-
test questionnaires regarding preferences for extended
endocrine therapy. Patients also completed the validated
traditional Decisional Conflict Scale (DCS) and State Trait
Anxiety Inventory forms (STAI-Y1) pre- and post-test. 96
patients were enrolled at the Yale Cancer Center [median
age 60.5 years (range 45–87), 79 % postmenopausal, 60 %
stage I). BCI predicted a low risk of late recurrence in
59 % of patients versus intermediate/high in 24 and 17 %,
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respectively. Physician recommendations for extended
endocrine therapy changed for 26 % of patients after
considering BCI results, with a net decrease in recom-
mendations for extended endocrine therapy from 74 to
54 %. After testing, fewer patients wanted to continue
extended therapy and decision conflict and anxiety also
decreased. Mean STAI and DCS scores were 31.3 versus
29.1 (p = 0.031) and 20.9 versus 10.8 (p\ 0.001) pre- and
post-test, respectively. Incorporation of BCI into risk/ben-
efit discussions regarding extended endocrine therapy
resulted in changes in treatment recommendations and
improved patient satisfaction.
Keywords Hormone therapy  Late recurrence 
Survivorship  Risk assessment  Anxiety  Satisfaction
Abbreviations
ER Estrogen receptor
BCI Breast Cancer Index
DCS Decisional conflict scale
STAI State Trait Anxiety Inventory
ROR PAM50 risk of recurrence
H/I HoxB13/IL17BR ratio
PR Progesterone receptor
HIC Human Investigations Committee
qRT-PCR Quantitative reverse transcription polymerase
chain reaction
FFPE Formalin-fixed paraffin-embedded tissue
Introduction
The risk of recurrence for many estrogen receptor (ER)
positive breast cancers extends over a prolonged period of
time and around 50 % of all recurrences develop after the
first 5 years of follow-up (‘‘late recurrence’’) [1]. Impor-
tantly, extended adjuvant endocrine therapy can reduce the
risk of late recurrences. In 5 different randomized con-
trolled trials (NCIC-CTG MA.17, NSABP-B33, ABCSG-
6a, ATLAS, and aTTom), which investigated either aro-
matase inhibitors following an initial 5 years of tamoxifen
[2–6] or 10 years of tamoxifen versus 5 years [7, 8],
extended endocrine therapy reduced the risk of late disease
recurrence. While these studies have established that
extended endocrine therapy is superior to 5 years of adju-
vant endocrine treatment; they also demonstrated that the
absolute benefit from prolonged endocrine therapy is
modest (approximately 3–5 % absolute benefit across
studies) and comes with added toxicity. For example, in the
ATLAS trial, 10 years of tamoxifen resulted in increased
risk for pulmonary embolism (RR 1.87, 95 % CI
1.13–3.07, p = 0.01) and endometrial cancer (RR 1.74,
95 % CI 1.30–2.34, p = 0.0002) [7]. The cumulative risk
of endometrial cancer during years 5–14 was 3.1 % for
10 years of tamoxifen compared to 1.6 % for 5 years [7,
9]. Extended adjuvant therapy with aromatase inhibitors
after tamoxifen also causes an increase in the risk for
osteoporosis, which may lead to unfavorable serum lipid
profiles, and is associated with arthralgias and menopause
side effects [4, 10]. In the MA17 trial, osteoporosis inci-
dence was 8.1 % in the letrozole group compared to 6 % in
controls (p = 0.003). Hot flashes, anorexia, arthralgia,
myalgia were also statistically significantly more common
in the letrozole arm [4]. Because of the modest efficacy,
potential for adverse events, and costs of therapy, there is
an unmet need for tools to help identify women who are at
risk for late recurrence and have endocrine sensitive can-
cers and therefore would benefit the most from prolonged
endocrine therapy [11, 12].
Clinical variable-based risk prediction models such as
Adjuvant! Online predict cumulative risk of recurrence
over a 10-year period but do not distinguish between risks
for early versus late relapse [13]. Furthermore, analyses
from the extended endocrine therapy clinical trials have
shown that clinicopathologic factors, including tumor size,
grade, nodal status, and quantitative ER are not predictive
for benefit from endocrine therapy [4, 6, 7, 14]. Recent
studies suggested that the 21-gene recurrence score (RS) is
most accurate to assess risk of recurrence in the first
5 years and is less useful to predict late recurrences [15–
18]. Several emerging molecular diagnostic assays
including the EndoPredict test, the PAM50 risk of recur-
rence (ROR) score, and the Breast Cancer Index (BCI) tests
have demonstrated the ability to specifically assess risk of
late recurrence in ER-positive cancers [14, 19–22]. BCI is
an 11-gene, gene-expression-based assay that incorporates
both a proliferation component and an estrogen signaling
component [19]. In addition to being validated in 2 ran-
domized trial cohorts as a prognostic tool for risk of late
recurrence, BCI also incorporates an endocrine response
biomarker (HoxB13/IL17BR ratio [H/I]), which has been
demonstrated in 3 randomized controlled trial cohorts to
predict benefit from endocrine therapy [14, 19, 23]. BCI
reports prognostic risk separately for early and late recur-
rence and also provides the likelihood of benefit from
extended endocrine therapy based on the H/I ratio. While
the test has been clinically validated, to-date, there have
not been studies to examine the clinical utility of the test on
treatment recommendations for extended endocrine ther-
apy. The primary objective of this study was to prospec-
tively assess the impact of the BCI results on physicians’
recommendation for extended adjuvant endocrine therapy
and to assess its effect on patient decision conflict, anxiety,
and satisfaction with the treatment recommendation.
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Methods
This study was approved by the Human Investigations
Committee (HIC) and all participants signed informed
consent.
Patients
All women with a history of ER or progesterone receptor
(PR) positive, stage I–III breast cancer, who have com-
pleted at least 3.5 years of adjuvant endocrine therapy and
were eligible for further extended adjuvant endocrine
therapy were offered participation in the study. The
research assistant identified eligible patients who were
coming to the breast cancer clinic for routine follow-up.
The research assistant alerted the treating physicians who
then discussed the study with the patient. Both the patient
and her treating physician had to agree to complete a pre-
test and a post-test questionnaire (Supplementary appen-
dix). Patient information including demographic data,
comorbid illnesses, breast cancer characteristics (TNM
stage, histologic grade, ER, PR, and HER status) and
treatment history including side effects from prior endo-
crine therapy was collected. Physicians were asked to
estimate the patient’s risk of recurrence, provide recom-
mendation for extended endocrine therapy, and indicate
confidence in the recommendation before testing and after
BCI test results became available. Patients reported their
perceived risk of recurrence, preference for extended
adjuvant therapy and completed the State Trait Anxiety
Index (STAI) and the traditional decision conflict scale
(DCS) instruments before and after testing (Supplementary
appendix). The STAI captures both transient anxiety (state
anxiety) and more long-standing anxiety (trait anxiety)
[24]. Participants in this study were asked to complete the
state anxiety (STAI-Y1) form only as trait anxiety is not
expected to be modifiable based on the knowledge of the
BCI results. The STAI-Y1 questionnaire includes 20 items
which are answered on a 1–4 scale, and the STAI-Y1 score
ranges from 20 to 80, with higher score correlating with
greater anxiety [24]. The DCS includes 16 statements and 5
Likert-scale response categories that measure personal
perceptions of uncertainty when choosing between options.
The score ranges from 0 to 100 and higher scores indicate
higher decisional conflict and greater difficulty in making a
decision [25]. Patients were also queried for concerns of
cost, side effects, safety and benefit, level of comfort with
the choice of extended therapy before and after the BCI
results, and impact on compliance. The median time
between completion of the pre- and post-test surveys was
92.5 days (range 21–364).
Molecular testing
BCI is an 11-gene, gene-expression-based (qRT-PCR)
assay performed on formalin-fixed paraffin-embedded
(FFPE) tissue (BioTheranostics; San Diego, CA). The BCI
assay yields a composite score indicating an individualized
percentage risk of late distant recurrence (post-5 years) and
a categorical (high vs. low) likelihood of benefit from
extended endocrine therapy. The assay represents the
combination of two distinct predictors [19]. The first is a
two-gene endocrine treatment sensitivity marker based on
the ratio of HOXB13 and IL17BR expression (H/I) [26,
27], the second is a proliferation marker represented by the
average expression of five cell cycle-associated genes
BUB1B, CENPA, NEK2, RACGAP1, and RRM2 [27].
The two markers together comprise a proprietary score that
ranges from 0 to 10, which is associated with an individ-
ualized risk of late recurrence, and is categorized into low
(BCI score\ 5.1), intermediate (5.1 B BCI score\ 6.5),
and high-risk (BCI score C 6.5) groups using previously
validated cut-points (note: the intermediate and high-risk
groups have similar risk of late recurrence in validation
studies) [19]. The BCI report includes 2 distinct elements:
an individualized risk of late (5–10 years) distant recur-
rence and a prediction of likelihood of benefit from
extended endocrine therapy based on the H/I biomarker.
While the assay provides an individualized assessment of
risk between years 5–10, data from one validation study did
show significant prognostic ability to year 15 post-diag-
nosis [19]. The BCI test was performed on archived tumor
tissues (primary tumor core biopsy or resection specimen)
and results were reported to the treating physician who
discussed results with the patient.
Statistical considerations
No prior data exist that describe the impact of the BCI
results on physician decision-making, therefore, we
assumed a recommendation change rate of 25 % (i.e.,
change from pre-test recommendation of no extended
therapy to post-test recommendation of extended therapy
or vice versa) which is similar to change rates observed
with Oncotype Dx. [28] The study was designed with a
sample size of 100 patients to allow estimation of this
change rate within an exact binomial 95 % confidence
interval half-width of 9 %. Data on physicians’ confidence
and patients’ comfort level regarding the treatment rec-
ommendation before and after BCI testing were compared
using McNemar’s test for paired data; odds ratios (OR)
were estimated by conditional logistic regression. The pre-
and post-test average DCS and STAI scores were compared
using a paired t test.
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Results
Patient and tumor characteristics
Between February and August 2014, 153 consecutive
patients with history of ER-positive, stage I–III breast
cancer currently receiving adjuvant endocrine therapy for
at least 3.5 years were screened for eligibility at the Breast
Center of Yale Cancer Center. Ninety-six patients met all
eligibility criteria, agreed to participate in the study, and
had sufficient tissue for testing. All 96 patients completed
both the pre-and post-test surveys. Figure 1 shows the
CONSORT diagram and Table 1 presents the patient
characteristics. The median age was 60.5 years (range
45–87), 70 patients had node negative disease, 58 had stage
I disease, and 49 patients received adjuvant or neoadjuvant
chemotherapy. Thirty patients were receiving adjuvant
tamoxifen and the rest an aromatase inhibitor when they
entered the study. Thirty patients had normal bone density,
and 49 had osteopenia on their most recent bone density
measurements within a year of study entry.
Summary of BCI test results
BCI categorized 57 patients as low risk, 23 as intermediate
risk, and 16 as high risk for late distant recurrence, while
56 and 40 patients were predicted to have low likelihood
and high likelihood of benefit from extended endocrine
therapy, respectively. The combinations of prognostic and
predictive categorizations are shown in supplementary
Table 1. In 43 cases, the assay predicted low risk of late
recurrence and a low likelihood of benefit from extended
endocrine therapy, while in 26 cases, the assay predicted a
high or intermediate risk of late recurrence and high like-
lihood of benefit from extended endocrine therapy. In 13
cases, patients had high or intermediate prognostic risk, but
no predicted benefit from extended endocrine therapy
(Supplementary Table 1).
Impact of BCI results on physician decision-making
Prior to the BCI test results, treating medical oncologists
assessed 49 % of patients to be low risk for recurrence
(defined as less than 5 % risk of recurrence after 5 years of
endocrine therapy). An additional 38 % were considered as
intermediate risk (i.e., predicted risk of recurrence 6–15 %)
and the remaining 13 % as high risk based on physician’s
judgment. The distribution of subjective risk estimates by
physicians with corresponding BCI results are shown in
Table 2. Prior to BCI testing, physicians recommended
extended endocrine therapy to the majority of patients (71
of 96 patients, 74 %) (Fig. 2). When extended endocrine
therapy was not recommended, the main reason was per-
ceived low risk of recurrence (n = 22) followed by risk of
osteoporosis (n = 4) and side effects from therapy (n = 3).
Following BCI testing, physicians changed treatment
decisions for 25 patients (26 %), Extended adjuvant ther-
apy was recommended to 52 (54 %) of patients, a statis-
tically significant reduction (OR = 0.14; 95 % CI
0.04–0.46; p = 0.0003; Fig. 2). The majority of the chan-
ges were in patients with low risk of late recurrence and
low likelihood of benefit. Changes in physician confidence
Parcipants consented and 
registered (n=105)
All eligible paents 
(n=153)
Excluded prior to registraon (n=48)
1. Treang physician did not feel the study was appropriate for the paent (n=30)
Considered clinically high risk by treang physician    (n=11)
Unable to complete quesonnaires (Psychological instability, comorbid illnesses, diﬃcules to follow the appointments 
- e.g. very elderly  or moving to another state) (n=17)
Newly diagnosed local recurrence of breast cancer (n=2)
2. Paent elected not to parcipate (n=7)
3. No ssue for tesng (n=1)
4. Lost for follow up aer inial contact (n=10)
Excluded post-registraon (n=5)
1. Insuﬃcient tumor ssue for tesng (n=5)





1. Developed metastac recurrence (n=1)
2. Withdrew consent (n=3)
Treang MDs (n=6)
Fig. 1 Consort diagram of the participants
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are shown in Fig. 3. More physicians felt strongly confi-
dent in their recommendation after the test result (24 %)
than before (8 %) (OR = 4.75; 95 % CI 1.62–13.96;
p = 0.0035) (Fig. 3).
Impact of BCI results on patient treatment
decisions, anxiety, and decision conflict
Table 2 shows how the BCI results were distributed across
the patient self-reported risk categories. When patients
were asked about their perceived risk of recurrence before
the test results were presented to them, 25 % indicated that
their disease was not likely to come back and 74 % felt that
it was somewhat likely that it could come back (Table 2).
Moreover, after BCI results were discussed with patients,
50 % felt that their disease was not likely to come back,
which represents a significant increase (OR = 9.0; 95 %
CI 2.73–29.67; p\ 0.0001), whereas a significantly
reduced number of patients (43 %) thought it was some-
what likely that it could come back (OR = 0.091; 95 % CI
0.028–0.296; p\ 0.0001). Six patients changed their risk
perception to high risk. Following discussion of BCI test
results with their physicians, 29 % fewer patients intended
to pursue extended endocrine therapy (58 vs. 82;
OR = 0.077; 95 % CI 0.018–0.324; p\ 0.0001) and sig-
nificantly more patients felt strongly comfortable with their
decision (51 vs. 26; OR = 3.78; 95 % CI 1.81–7.88;
p = 0.0003; Fig. 3).
Mean STAI scores decreased from 31.3 before BCI
testing to 29.1 following testing, a significant reduction in
overall anxiety level (paired t test p-value = 0.031). At the
individual patient level, anxiety level decreased in 54
patients, remained stable in 12 patients, and increased in 30
patients (Fig. 4). Mean DCS scores also improved fol-
lowing BCI testing (20.9 to 10.8; paired t test p\ 0.001).
At the individual patient level, decision conflict decreased
in 62 patients, remained stable in 18 patients, and increased
in 16 patients (Fig. 4; supplementary Table 2). Sixty-nine
percent of patients reported that knowing BCI test results
made them more likely to be compliant with extended
endocrine therapy.
Table 1 Patient and tumor characteristics
Patient and tumor characteristics (n = 96) %
Median age (min–max) 60.5 (45–87)
\50 years old 11 12
C50 years old 85 88
Caucasian 87 91
African American 5 5
Asian 2 2





ER positive 96 100
ER negative 0
PR positive 85 88
PR Negative 11 12
HER2 positive 9 9
HER2 negative 86 90
HER2 not available 1 1
Histologic grade
Grade 1 30 31
Grade 2 50 52
Grade 3 16 17
TNM stage (AJCC)
Stage I 58 60
Stage II 33 35
Stage III 5 5
Tumor size at diagnosis
T1 (B2 cm) 65 68
T2 ([2–5 cm) 32 33
T3 ([5 cm) 3 3
T4 (skin involvement) 0
Nodal status at diagnosis
N0 (no nodal involvement) 70 73
N1 (1–3 nodes) 22 23
N2 (4–9 nodes) 4 4














Patient and tumor characteristics (n = 96) %
Osteopenia 49 51
Osteoporosis 5 5
Not available 12 13
n number of the patients, ER estrogen receptor PR progesterone
receptor HER2 human epidermal growth factor receptor 2
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Extended Endocrine Treatment Recommendaon
A B
Pre Test Post Test
Paent Preference on Extension of Endocrine Therapy
Pre Test Post Test
Fig. 3 Medical oncologists’
pre-test and post-test level of
confidence in treatment
recommendation stratified based
on whether extended endocrine
treatment was recommended in
the pre-test and post-test setting
(a). Patients’ pre-test and post-
test levels of comfort with the
decision for extended adjuvant
endocrine treatment stratified
based on whether patients
preferred extended endocrine
treatment in the pre-test and
post-test setting (b)
Table 2 Subjective risk estimates of patients and physicians versus the Breast Cancer Index (BCI) risk prediction results
Pre-test recurrence risk perception (risk of relapse
after 5 years of endocrine treatment)
Number of
patients (% total)
Patients in Breast Cancer Index (BCI) risk groups (% in risk category)
Low risk Intermediate risk High risk
By physicians
Low risk (0–5 %) 47 (49) 35 (75) 10 (31) 2 (4)
Intermediate (6–15 %) 37 (38) 18 (49) 9 (24) 10 (27)
High ([15 %) 12 (13) 4 (33) 4 (33) 4 (34)
Total 96 (100) 57 (59) 23 (24) 16 (17)
By patients
Not at all likely 24 (25) 17 (71) 5 (21) 2 (8)
Somewhat likely 71 (74) 39 (55) 18 (25) 14 (20)
Very likely 1 (1) 1 (100) 0 0
Total 96 (100) 57 (59) 23 (24) 16 (17)
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Discussion
This is the first study to prospectively assess the decision-
making impact of BCI assay in a routine clinical practice
setting in patients who face the decision to continue with
extended adjuvant endocrine therapy or stop at 5 years.
The results indicate that the test results had a significant
effect on both physician treatment recommendation and
patient satisfaction. Overall, knowledge of the BCI result
led to fewer recommendations for extended endocrine
therapy and improved patient satisfaction, and reduced
anxiety and decision conflict. We noted that the physicians
default tendency was to recommend extended endocrine
therapy, consistent with ASCO guidelines and randomized
clinical trial results, and patients also favored longer
duration of therapy (presumably preferring to err on the
cautionary side with potential to reduce the risk of cancer
recurrence). This observation is consistent with a recent
report that also found that 64 % of physicians recom-
mended extended adjuvant endocrine therapy for eligible
patient and 85 % of patients have accepted the recom-
mended treatment [29]. The study results suggest that these
choices may be largely based on inflated risk perception.
Before testing, 75 % of patients thought that their cancer is
very likely or somewhat likely to recur compared to 50 %
after the test results became available. Physician estimation
of risk of late recurrence was also frequently discordant
with the molecular risk assessment result. Prior to knowing
the BCI test results, physicians estimated a high risk of
recurrence ([16 %) in 12 patients (13 %). Of these
patients, the BCI test was high risk in 33 %, intermediate in
33 %, and low in 33 %. In two cases, the low-risk category
results lead to recommendations to forgo extended endo-
crine therapy. Conversely, 49 % of those estimated by
physicians to have an intermediate (6–15 %) risk of
recurrence had a low risk BCI. The net effect of testing was
a decreased perception of risk of late recurrence and
reduced recommendation rate for extended endocrine
therapy. As expected, when a therapeutic decision is sup-
ported by a test result that is perceived as objective, the
comfort level with the treatment recommendation increases
for both physicians and patients. However, when the clin-
ical risk estimate and molecular risk estimate are widely
discordant, this could increase anxiety and ambivalence,
which we also observed in a minority of cases.
The results of this study are relevant within the context
of the evolving standard of chronic care for patients with
early-stage ER-positive breast cancer. Following the
completion of the landmark extended adjuvant endocrine
therapy trials, more patients are being recommended for
10 years of adjuvant endocrine therapy; however, without
patient selection, the number-needed-to-treat is high.
Assessment of risk vs benefit, particularly for patients with













A BFig. 4 STAI (a) and DCS
(b) scores for individual patients
before and after BCI assay.
Each line connects the pre- and
post-test STAI and DCS scores
for an individual (n = 96
patients). Increasing values
post-test are shown in blue and
decreasing values are shown in
red. n number of the patients,
STAI state trait anxiety index,
DCS decision conflict scale, BCI
Breast Cancer Index
Breast Cancer Res Treat (2015) 154:533–541 539
123
likelihood of benefit from extended therapy against the
potential for serious toxicities, tolerability, and quality of
life considerations. The findings herein suggest that inte-
grating validated genomic information to help stratify
patients based on individualized risk of late recurrence and
likelihood of benefit from extended endocrine therapy
impacted risk vs benefit discussions and treatment recom-
mendations. Finally, these results may have implications in
the context of survivorship program initiatives [30], as a
greater proportion of patients reported strong comfort with
their treatment decisions as well as reductions in patient
anxiety and decision conflict.
This study has several limitations. First, we did not
regulate the nature of information exchange between
physicians and patients, but recognize that how the test
results were communicated could have impacted patient
perception about its value. This limitation can also be
perceived as a practical strength since the results reflect the
outcome of typical patient–physician interactions as they
take place in the clinic. This study does not address the
prognostic and predictive accuracy of the BCI test, which
has been published in a series of peer-reviewed manu-
scripts previously [14, 19, 20]. The patient population was
mostly Caucasian and from an academic medical center
which may limit the generalizability of the results.
In summary, extended endocrine therapy decision-
making has been challenging, given the high number of
patients needed to treat in order to obtain benefit and the
well-established safety and tolerability challenges with
endocrine therapies [11]. Incorporation of BCI assay test-
ing led to altered medical recommendation in 26 % of
cases, fewer recommendations for extended endocrine
therapy, and improved patient satisfaction.
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